APA (7th ed.) Citation

AKS, S., V, W., ER, M., JI, P., HX, C., RJ, G., . . . KT, F. (2026). Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H. JCO precision oncology, 10, e2500338. https://doi.org/10.1200/PO-25-00338

Chicago Style (17th ed.) Citation

AKS, Salama, et al. "Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H." JCO Precision Oncology 10 (2026): e2500338. https://doi.org/10.1200/PO-25-00338.

MLA (9th ed.) Citation

AKS, Salama, et al. "Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H." JCO Precision Oncology, vol. 10, 2026, p. e2500338, https://doi.org/10.1200/PO-25-00338.